Compare SOPA & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOPA | SCYX |
|---|---|---|
| Founded | 2018 | 1999 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.0M | 26.3M |
| IPO Year | 2021 | 2014 |
| Metric | SOPA | SCYX |
|---|---|---|
| Price | $2.22 | $0.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $22.50 | $3.00 |
| AVG Volume (30 Days) | ★ 15.0M | 513.5K |
| Earning Date | 11-14-2025 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,227,427.00 | $2,932,000.00 |
| Revenue This Year | $2.43 | $170.77 |
| Revenue Next Year | $71.20 | $286.38 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 4.65 | N/A |
| 52 Week Low | $0.64 | $0.57 |
| 52 Week High | $6.75 | $1.31 |
| Indicator | SOPA | SCYX |
|---|---|---|
| Relative Strength Index (RSI) | 48.34 | 70.59 |
| Support Level | $2.12 | $0.63 |
| Resistance Level | $2.78 | $0.87 |
| Average True Range (ATR) | 0.30 | 0.05 |
| MACD | -0.09 | 0.02 |
| Stochastic Oscillator | 8.05 | 71.12 |
Society Pass Inc is building an ecosystem of platforms and technology-enabled companies that synergistically work together to transform how consumers and merchants interact with one another in Southeast Asia and South Asia. Through the acquisition of companies and partnerships with entrepreneurs, the company meets the growing demand for services in sectors such as lifestyle, beauty, travel, and food and beverage. The company currently operates in Six reportable operating segments: Online Grocery and Food deliveries, Digital marketing, Online ticketing and reservation, Telecommunications Reseller, e-commerce, and Corporate. The company generates the majority of its revenue from the Digital marketing segment.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.